Bioperfectus 𝐂𝐎𝐕𝐈𝐃-𝟏𝟗 𝐂𝐨𝐫𝐨𝐧𝐚𝐯𝐢𝐫𝐮𝐬 𝐑𝐞𝐚𝐥 𝐓𝐢𝐦𝐞 𝐏𝐂𝐑 𝐊𝐢𝐭, 𝐂𝐎𝐕𝐈𝐃-𝟏𝟗 𝐂𝐨𝐫𝐨𝐧𝐚𝐯𝐢𝐫𝐮𝐬 (𝐎𝐑𝐅𝟏𝐚𝐛/𝐍/𝐄) 𝐑𝐞𝐚𝐥 𝐓𝐢𝐦𝐞 𝐏𝐂𝐑 𝐊𝐢𝐭, 𝐂𝐎𝐕𝐈𝐃-𝟏𝟗 𝐂𝐨𝐫𝐨𝐧𝐚𝐯𝐢𝐫𝐮𝐬 𝐚𝐧𝐝 𝐈𝐧𝐟𝐥𝐮𝐞𝐧𝐳𝐚 𝐀/𝐁 𝐕𝐢𝐫𝐮𝐬 𝐑𝐞𝐚𝐥 𝐓𝐢𝐦𝐞 𝐏𝐂𝐑 𝐊𝐢𝐭 are not affected by the Omicron subvariant BA.5.1.3, an offshoot of the BA.5 strain and BF.15, a new mutation of the omicron subvariant BA.5.2.1
Type of packaging matters. In the era of the post-COVID-19 pandemic, the cost-efficiency of nucleic acid extraction is one of the primary concerns of many PCR laboratories.
BioPerfectus is pleased to announce that Monkeypox Virus (MPXV) Fast Real Time PCR Kit, Monkeypox Virus Genotyping Real Time PCR Kit, Monkeypox Virus/Varicella-zoster Virus/Variola Virus Real Time PCR Kit, Monkeypox Virus and Orthopoxvirus Real Time PCR Kit have been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and are now officially available for Great Britain and Northern Ireland market.
Nucleic acid extraction provides a foundation for many extensive research and applications (for example cloning, PCR analysis, and next-generation sequencing technology in the field of whole genome and transcriptome), and the obtained nucleic acid can be used in a variety of ways. Nucleic acid purification and quality assessment are important steps in experimental workflows, and the quality of nucleic acids can affect the performance in downstream reactions.
Infectious diseases spread rapidly, and individuals with viruses can spread the infection to many other people in their community. Bioperfectus is still in a race against time and a guardian of humankind.
Nowadays, emerging infectious diseases significantly threaten global public health and socioeconomic security and will change how people live. COVID-19 is a notable example. There might also have an outbreak of Monkeypox based on the current situation. When a disease outbreak occurs, PCR would be a suitable way to accurately identify the pathogen and detect it in the early stage.
Since 1 January 2022, cases of monkeypox have been reported with almost 60,000 in102 countries and regions. As data presented that about 99% of cases in 95 locations have not been historically reported. This is the first time that cases and sustained chains of transmission have been reported in countries without direct or immediate epidemiological links to areas of West or Central Africa.
In this turbulent world, 𝐰𝐨𝐦𝐞𝐧 𝐡𝐚𝐯𝐞 𝐮𝐧𝐢𝐪𝐮𝐞 𝐡𝐞𝐚𝐥𝐭𝐡 𝐜𝐚𝐫𝐞 𝐜𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞𝐬 𝐚𝐧𝐝 𝐚𝐫𝐞 𝐚𝐭 𝐡𝐢𝐠𝐡𝐞𝐫 𝐫𝐢𝐬𝐤 𝐨𝐟 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐢𝐧𝐠 𝐜𝐞𝐫𝐭𝐚𝐢𝐧 𝐜𝐨𝐧𝐝𝐢𝐭𝐢𝐨𝐧𝐬 𝐚𝐧𝐝 𝐝𝐢𝐬𝐞𝐚𝐬𝐞𝐬 𝐭𝐡𝐚𝐧 𝐦𝐞𝐧. Women's health includes a wide range of specialties and focuses areas.
Bioperfectus Cervical Cancer Screening Total PCR Solution embraces the WHO 90-70-90 target. It helps realize the key pillar- 70% of women screened using a high-performance test by age 35 and again by age 45.
Bioperfectus deliver strong financial performance in the first half of 2022
